12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Incivek telaprevir: Interim Phase IIIb data

Interim data from 85 evaluable patients in the 12-week treatment arm of the open-label, placebo-controlled, international Phase IIIb CONCISE trial showed that twice-daily 1,125 mg Incivek plus peginterferon and ribavirin for 12 weeks led to an SVR 12 weeks after end of treatment in 87% of patients. In 30 evaluable patients in the 24-week treatment arm of the trial, twice-daily 1,125 mg Incivek plus peginterferon and ribavirin for 12 weeks followed by peginterferon and ribavirin alone for 12 weeks...

Read the full 374 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >